NCT07422363 2026-03-18
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
Clinical Trials
27 trialsNCT07472790 2026-03-16
A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase 1 Not yet recruiting
NCT06502171 2026-03-12
NF113
University of Alabama at Birmingham
Phase 1 Not yet recruiting
NCT07464925 2026-03-11
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Tetragon Biosciences Ltd
Phase 1 Not yet recruiting
NCT07457307 2026-03-09
INSIGHT MRL
NYU Langone Health
Phase 1 Not yet recruiting
NCT07454668 2026-03-06
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
Baptist Health South Florida
Phase 1 Not yet recruiting
NCT07455045 2026-03-06
A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT07441707 2026-03-02
A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours
Ipsen
Phase 1 Not yet recruiting
NCT07438860 2026-02-27
Fluorescence-Guided Imaging of Brain Tumors: A Safety Study Using SBK2-ICG
Case Comprehensive Cancer Center
Phase 1 Not yet recruiting
NCT07076498 2026-02-25
Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07422896 2026-02-20
Bvax
Northwestern University
Phase 1 Not yet recruiting
NCT07218367 2026-02-13
Phase I Trial of pH Resections of GBM at VA
VA Office of Research and Development
Phase 1 Not yet recruiting
NCT07211737 2026-02-06
NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
Baylor College of Medicine
Phase 1 Not yet recruiting
NCT07390539 2026-02-05
B7-H3.CD28Z.CART in CNS Neoplasms
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07385846 2026-02-04
Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency
University of Cincinnati
Phase 1 Not yet recruiting
NCT07358260 2026-01-22
B7-H3.CD28Z.CART in Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT06357377 2026-01-14
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
Neonc Technologies, Inc.
Phase 1 Not yet recruiting
NCT07331064 2026-01-09
GABRIEL
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT04903795 2025-11-03
BRiTE
Duke University
Phase 1 Not yet recruiting
NCT07199413 2025-09-30
Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT07185880 2025-09-22
STAR-GBM
Myosin Therapeutics Inc.
Phase 1 Not yet recruiting
NCT06455189 2025-08-13
Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas
Case Comprehensive Cancer Center
Phase 1 Not yet recruiting
NCT06737146 2024-12-17
Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma
Suzhou Maximum Bio-tech Co., Ltd.
Phase 1 Not yet recruiting
NCT04933422 2024-08-21
CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)
Crimson Biopharm Inc.
Phase 1 Not yet recruiting
NCT06524063 2024-07-29
Targeted Survivin DC Cell Injection for the Treatment of GBM
Beijing Tricision Biotherapeutics Inc
Phase 1 Not yet recruiting
NCT06132438 2023-11-15
Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma
The University of New South Wales
Phase 1 Not yet recruiting
NCT05095441 2022-10-12
A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma
ImmVira Pharma Co. Ltd
Phase 1 Not yet recruiting